ALNYLAM PHARMACEUTICALS, INC.

Form 4 July 02, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(City)

1 Title of

(State)

2 Transaction Data 2A D

(Zip)

(Print or Type Responses)

1. Name and Adda MARAGANO	-	ng Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
			ALNYLAM PHARMACEUTICALS, INC. [ALNY]	(Check all applicable) X Director 10% Owner			
(Last) 300 THIRD ST	(First) TREET	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/29/2007	X Officer (give title Other (specify below) CEO			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
CAMBRIDGE, MA 02142				Form filed by More than One Reporting Person			

Tau	ne 1 - 140	n-Derivative Securities Acq	un eu, Disposeu	oi, or belieficial	ly Owneu
Deemed	3.	4. Securities Acquired	5. Amount of	6. Ownership	7. Nature of
ution Date, if	Transa	action(A) or Disposed of (D)	Securities	Form: Direct	Indirect

1.1itle of	2. Transaction Date	2A. Deemed	3.	4. Securi		*	5. Amount of	6. Ownership	
Security	(Month/Day/Year)	Execution Date, if	Transactio	n(A) or Disposed of (D)		Securities	Form: Direct	Indirect	
(Instr. 3)		any	Code	(Instr. 3,	(Instr. 3, 4 and 5)		Beneficially	(D) or	Beneficial
		(Month/Day/Year)	(Instr. 8)				Owned	Indirect (I)	Ownership
							Following	(Instr. 4)	(Instr. 4)
					(A)		Reported		
					or		Transaction(s)		
			Code V	Amount		Price	(Instr. 3 and 4)		
Common	06/29/2007		S(1)	700	D	\$ 15.6	18,078	D	
Stock	00/2/12007		<u> </u>	700	ט	Ψ 15.0	10,070	D	
Common						¢			
Common	06/29/2007		S	1,300	D	ه 15.61	16,778	D	
Stock						15.61			
Common						\$			
Stock	06/29/2007		S	1,100	D	15.62	15,678	D	
Stock						13.02			
Common	06/20/2007		C	1 001	Ъ	\$	12 707	D	
Stock	06/29/2007		S	1,891	ע	15.63	13,787	D	
Common	06/29/2007		S	1,100	D	\$	12,687	D	
Stock	0012712001		3	1,100	D	15.64	12,007	D	

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock	06/29/2007	S	1,000	D	\$ 15.65	11,687	D
Common Stock	06/29/2007	S	1,300	D	\$ 15.66	10,387	D
Common Stock	06/29/2007	S	300	D	\$ 15.67	10,087	D
Common Stock	06/29/2007	S	365	D	\$ 15.69	9,722	D
Common Stock	06/29/2007	S	535	D	\$ 15.7	9,187	D
Common Stock	06/29/2007	S	100	D	\$ 15.72	9,087	D
Common Stock	06/29/2007	S	382	D	\$ 15.76	8,705	D
Common Stock	06/29/2007	S	118	D	\$ 15.78	8,587	D
Common Stock	06/29/2007	S	1,000	D	\$ 15.8	7,587	D
Common Stock	06/29/2007	S	500	D	\$ 15.81	7,087	D
Common Stock	06/29/2007	S	600	D	\$ 15.82	6,487	D
Common Stock	06/29/2007	S	800	D	\$ 15.86	5,687	D
Common Stock	06/29/2007	S	100	D	\$ 15.87	5,587	D
Common Stock	06/29/2007	S	600	D	\$ 15.88	4,987	D
Common Stock	06/29/2007	S	100	D	\$ 15.89	4,887	D
Common Stock	06/29/2007	S	300	D	\$ 15.9	4,587	D
Common Stock	06/29/2007	S	700	D	\$ 16	3,887	D
Common Stock	06/29/2007	S	300	D	\$ 16.01	3,587	D
Common Stock	06/29/2007	S	100	D	\$ 16.02	3,487	D
Common Stock	06/29/2007	S	100	D	\$ 16.03	3,387	D
	06/29/2007	S	200	D		3,187	D

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock					\$ 16.04	
Common Stock	06/29/2007	S	300	D	\$ 16.05 2,887	D
Common Stock	06/29/2007	S	600	D	\$ 16.06 2,287	D
Common Stock	06/29/2007	S	100	D	\$ 16.09 2,187	D
Common Stock	06/29/2007	S	498	D	\$ 16.1 1,689	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
•	Director	10% Owner	Officer	Other				
MARAGANORE JOHN 300 THIRD STREET CAMBRIDGE, MA 02142	X		CEO					

Signatures

By: Patricia L Allen, Attorney-in-Fact For: John M
Maraganore

07/02/2007

Reporting Owners 3

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2007.

Remarks:

This Form 4 is the second of three filed by the reporting person to report transactions occurring on June 29, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4